Exicure, Inc. (XCUR)

0.1227 +0.0077 (+6.70%) At close: 04:00PM EDT

Exicure, Inc.

2430 North Halsted Street
Chicago, IL 60614
United States
847 673 1700
https://www.exicuretx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 47

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Matthias G. Schroff Ph.D.	CEO, Pres & Director	479.09k	N/A	1969
Mr. Brian C. Bock	Special Advisor	449.29k	N/A	1977
Mr. Elias D. Papadimas	CFO & Corp. Sec.	N/A	N/A	1976
Ms. Sarah Longoria	Chief HR & Compliance Officer	N/A	N/A	1982
Mr. Bart Anderson	Sr. Director of R&D	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Corporate governance

Exicure, Inc.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.